A Randomized, Double-blind, Placebo-controlled Pilot Study to Assess the Safety and Efficacy of Ifetroban for the Treatment of Portal Hypertension in Cirrhotic Patients

Trial Profile

A Randomized, Double-blind, Placebo-controlled Pilot Study to Assess the Safety and Efficacy of Ifetroban for the Treatment of Portal Hypertension in Cirrhotic Patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Ifetroban (Primary) ; Ifetroban (Primary)
  • Indications Liver cirrhosis; Portal hypertension
  • Focus Adverse reactions
  • Sponsors Cumberland Pharmaceuticals
  • Most Recent Events

    • 14 Sep 2016 According to a Cumberland Pharmaceuticals media release, status changed from not yet recruiting to recruiting.
    • 14 Sep 2016 According to a Cumberland Pharmaceuticals media release, the US FDA has cleared an IND for ifetroban facilitating initiation of this trial.
    • 22 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top